Haemonetics Corporation (NYSE:HAE) Director Pedro P. Granadillo sold 7,118 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $57.06, for a total transaction of $406,153.08. Following the transaction, the director now directly owns 31,663 shares in the company, valued at $1,806,690.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Haemonetics Corporation (NYSE HAE) opened at $57.10 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a 1-year low of $36.44 and a 1-year high of $58.99. The company has a market cap of $3,072.44, a price-to-earnings ratio of 35.69, a P/E/G ratio of 4.37 and a beta of 0.99.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to analyst estimates of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.38 EPS. equities analysts anticipate that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.
Several analysts have commented on the stock. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, November 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 target price (up previously from $38.00) on shares of Haemonetics in a research note on Friday, October 6th. Craig Hallum reiterated a “hold” rating and issued a $50.00 target price (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Barrington Research boosted their price objective on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $53.33.
Large investors have recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Haemonetics in the 2nd quarter worth about $132,000. Riverhead Capital Management LLC grew its position in Haemonetics by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares during the last quarter. Pacad Investment Ltd. bought a new position in Haemonetics during the 2nd quarter valued at about $174,000. Shelton Capital Management bought a new position in Haemonetics during the 2nd quarter valued at about $204,000. Finally, Cubist Systematic Strategies LLC bought a new position in Haemonetics during the 2nd quarter valued at about $260,000.
TRADEMARK VIOLATION NOTICE: “Pedro P. Granadillo Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/15/pedro-p-granadillo-sells-7118-shares-of-haemonetics-corporation-hae-stock.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.